Juno Therapeutics, A Subsidiary Of Celgene
Clinical trials sponsored by Juno Therapeutics, A Subsidiary Of Celgene, explained in plain language.
-
New CAR T-Cell therapy shows promise for Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a treatment called JCAR017, which uses a patient's own immune cells to fight cancer. It is for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to other treatments. The study will test JCAR017 …
Phase: PHASE1, PHASE2 • Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
Second chance: lymphoma patients get access to imperfect but potentially lifesaving CAR T-Cell therapy
Disease control AVAILABLEThis program gives people with large B-cell lymphoma access to a CAR T-cell therapy called lisocabtagene maraleucel (liso-cel) when their specific batch didn't pass all quality checks. Participants receive chemotherapy before the treatment. The goal is to offer a potential benefi…
Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated May 20, 2026 11:54 UTC